Drug Trial Radar · NCT02998879
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis
Last checked: Nov 20, 2026Latest source record: Oct 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Dec 2016
Primary completion
Jul 2020
Study completion Jul 2020
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- Cromsource
- First posted
- Dec 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of the study are to evaluate safety and efficacy of repeated treatment with recombinant human alfa-mannosidase of patients with alfa-mannosidosis aged less than 6 years
Conditions
- Alpha-Mannosidosis
Interventions
Velmanase Alfa (e.g. Lamazym)Drug
iv infusion treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of velmanase alfa as per Adverse eventsTime frame: From baseline throughout study completion, at least of 2 years
- Safety and tolerability of velmanase alfa as per vital signsTime frame: From baseline throughout study completion, at least of 2 years
- Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per hematologyTime frame: From baseline throughout study completion, at least of 2 years
- Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per blood biochemistryTime frame: From baseline throughout study completion, at least of 2 years
- Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per urinalysisTime frame: From baseline throughout study completion, at least of 2 years
- Detection of anti-velmanase alfa-IgG antibodies (ADA) and neutralizing/inhibitory antibodiesTime frame: From baseline throughout study completion, at least of 2 years
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Vienna, Austria
Site not named
Copenhagen, Denmark
Site not named
Lyon, France
Site not named
Hamburg, Germany
Site not named
Mainz, Germany
Site not named
Trieste, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.